Three major US firms back India’s drug patent regime

Source: Economic Times

1 May 2014

NEW DELHI: Three major US companies – Boeing, AbbottBSE 0.21 % and HoneywellBSE 1.19 % – have come in support of India’s IPR regime, which has come under attack by American pharma sector for alleged violations of global norms.

America’s major defence company Honeywell, civil aviation firm Boeing and drug major Abbott have come out strongly in support of India’s IPR regulations.

Aviation major Boeing has said India has a strong legal framework to protect such rights, pharma company Abbott has stated that it is “not currently facing any significant challenges with respect to intellectual property protection in India”.

In its remarks submitted to the US Trade Commission (USITC), a quasi-judicial body, Boeing has said: “In Boeing’s experience, India has a legal framework that is adequate to protect IP with no known cases of IP violation involving Boeing’s activities in the defense and aerospace sector.”

Similarly, Honeywell International has said that an acceptable IPR legal framework exists in India.

“…India’s IPR framework was one of the key enablers in the establishment of Honeywell’s engineering and technology presence,” it has said.

Abbott too have said that India is an investment priority and fundamentally important to the future of the company.

“We have had a positive experience in India, (we) are committed to a long-term presence, and remain optimistic about ..
“We have had a positive experience in India, (we) are committed to a long-term presence, and remain optimistic about our future…,” Abbott has said in a five-page note.

These statements assume significance on the backdrop of US industry, particularly the pharmaceuticals sector, and trade lobbies putting pressure on their government to place India under the Priority Foreign Country list for IPR.

Under the US Trade Act, a Priority Foreign Country is the worst classification given to those that deny adequate and effective protection of IPR or fair and equitable market access to US entities relying on IPR protection.

The US Trade Representative (USTR) is scheduled to come out with a report on April 30 on Special 301, which talks about IPR regime of countries. The US trade law requires an annual review of intellectual property protection and market access practices in foreign countries.

The Special 301 Report highlights the economic importance of IP to the US economy and details other countries’ IP protection and enforcement-related efforts.

This entry was posted in Indian Patent Law, Patents, Special 301 report, US pressure on India. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s